volume 30, issue s2, PS269-S282 2012
DOI: 10.3233/jad-2012-111664
View full text
|
|
Share
William V. Goodison, Vincenza Frisardi, Patrick G. Kehoe

Abstract: Midlife hypertension is a risk factor for late onset Alzheimer's disease (AD) and it is one of the components of metabolic syndrome (MetS). Observational studies and some cardiovascular disease-related clinical trials suggest that antihypertensive treatment reduced the incidence and progression of AD. Calcium channel blockers (CCBs), one of the more commonly used treatments for hypertension, target voltage-gated calcium channels (VGCCs) which are found on neurons in the brain where calcium regulation is very i…

expand abstract